Benign Breast Disease and Breast Cancer Risk: Morphology and Beyond

Evidence from clinical follow-up studies has indicated that there is a relationship between the presence of histologically proven benign breast disease and breast cancer risk and that the level of risk varies according to the histologic category of benign breast disease. In particular, proliferative lesions without atypia are associated with a 1.5- to 2-fold increase in risk, whereas atypical hyperplasias are associated with a fourfold to fivefold increase in breast cancer risk. A number of clinical factors appear to modify the risk associated with these lesions, including the time since biopsy, menopausal status, and family history of breast cancer. Recent studies have begun to evaluate the potential role of biologic, molecular, and genetic markers in assessing breast cancer risk in patients with benign breast disease. Additional information derived from clinicopathologic follow-up studies, epidemiologic studies, and molecular and genetic studies will provide new insights into benign breast disease and breast cancer risk.

[1]  D. Barnes,et al.  Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia , 1998, The Journal of pathology.

[2]  C. Bodian,et al.  Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type--benign and malignant intraductal proliferations. , 1999, The American journal of surgical pathology.

[3]  A. Miller,et al.  Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. , 1998, Journal of the National Cancer Institute.

[4]  L. Brinton,et al.  Breast cancer risk associated with proliferative breast disease and atypical hyperplasia , 1993, Cancer.

[5]  R. Lattes,et al.  Reproducibility and validity of pathologi classifications of benign breast disease and implications for clinical applications , 1993, Cancer.

[6]  M. Merino,et al.  Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions , 1995, Nature Medicine.

[7]  W. Dupont,et al.  Atypical hyperplastic lesions of the female breast: A long-term follow-up study , 1986 .

[8]  R. Hutter Goodbye to "fibrocystic disease". , 1985, The New England journal of medicine.

[9]  D. Kodlin,et al.  Chronic mastopathy and breast cancer: A Follow‐Up Study , 1977, Cancer.

[10]  G. Colditz,et al.  Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk , 2000, Cancer.

[11]  W. Dupont,et al.  Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. , 1989, Human pathology.

[12]  M. Meguid,et al.  Estrogen receptor expression in benign breast epithelium and breast cancer risk. , 1998, Journal of the National Cancer Institute.

[13]  L. Melton,et al.  HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Bodian,et al.  Prognostic significance of benign proliferative breast disease , 1993, Cancer.

[15]  S. Love,et al.  Fibrocystic Disease of the Breast — A Nondisease? , 1982 .

[16]  S. Bianchi,et al.  Benign breast disease and breast cancer: A case‐control study in a cohort in italy , 1991, International journal of cancer.

[17]  D. Henson,et al.  Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. , 1998, Archives of pathology & laboratory medicine.

[18]  R. Mansel,et al.  ABERRATIONS OF NORMAL DEVELOPMENT AND INVOLUTION (ANDI): A NEW PERSPECTIVE ON PATHOGENESIS AND NOMENCLATURE OF BENIGN BREAST DISORDERS , 1987, The Lancet.

[19]  P. Wingo,et al.  Histologic types of benign breast disease and the risk for breast cancer , 1992, Cancer.

[20]  P. Taylor,et al.  A prospective study of the development of breast cancer in 16,692 women with benign breast disease. , 1988, American journal of epidemiology.

[21]  G. Colditz,et al.  Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  S. Love,et al.  Sounding board. Fibrocystic "disease" of the breast--a nondisease? , 1982, The New England journal of medicine.

[23]  Simpson,et al.  Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in‐situ and invasive carcinomas , 2000, Histopathology.

[24]  R. Laucirica,et al.  p53 accumulation in benign breast biopsy specimens. , 1995, Human pathology.

[25]  W D Plummer,et al.  Understanding the relationship between relative and absolute risk , 1996, Cancer.

[26]  J. Rosai,et al.  Borderline Epithelial Lesions of the Breast , 1991, The American journal of surgical pathology.

[27]  R. Millikan,et al.  p53 mutations in benign breast tissue. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Paúl,et al.  Education, leisure activities and cognitive and functional ability of Alzheimer's disease patients: A follow-up study , 2013, Dementia & neuropsychologia.

[29]  R. Sutherland,et al.  Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  W. Dupont,et al.  Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk , 1989, Cancer.

[31]  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. , 1997, Lancet.

[32]  S J London,et al.  A prospective study of benign breast disease and the risk of breast cancer. , 1992, JAMA.

[33]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[34]  A. Zetterberg,et al.  Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. , 1994, Human pathology.

[35]  David L. Page,et al.  Anatomic indicators (histologic and cytologic) of increased breast cancer risk , 1993, Breast Cancer Research and Treatment.

[36]  R. Hiatt,et al.  Risk of breast cancer after benign breast diseases. Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. , 1992, American journal of epidemiology.

[37]  D. Weiner,et al.  Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[38]  N. Ordóñez,et al.  Extranodal Follicular Dendritic Cell Sarcoma of the Head and Neck Region: Three New Cases, with a Review of the Literature , 2002, Modern Pathology.

[39]  D. Page,et al.  Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. , 1992, Human pathology.

[40]  A. Bankfalvi,et al.  Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast , 2000, Histopathology.

[41]  G. Colditz,et al.  Radial scars in benign breast-biopsy specimens and the risk of breast cancer. , 1999, The New England journal of medicine.

[42]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[43]  S J Schnitt,et al.  Interobserver Reproducibility in the Diagnosis of Ductal Proliferative Breast Lesions Using Standardized Criteria , 1992, The American journal of surgical pathology.

[44]  J. Sloane,et al.  Histopathologic Types of Benign Breast Lesions and the Risk of Breast Cancer: Case–Control Study , 2002, The American journal of surgical pathology.

[45]  G. Colditz,et al.  Pathologic features of breast cancers in women with previous benign breast disease. , 2001, American journal of clinical pathology.

[46]  W. Dupont,et al.  Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk. , 1988, Human pathology.

[47]  S. Heffelfinger,et al.  Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  J. Bahi,et al.  Angiogenesis and risk of breast cancer in women with fibrocystic disease. , 1994, Journal of the National Cancer Institute.

[49]  N. Sneige,et al.  Molecular and Biologic Markers of Premalignant Lesions of Human Breast , 2002, Advances in anatomic pathology.

[50]  F. Tavassoli,et al.  A comparison of the results of long‐term follow‐up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast , 1990, Cancer.